The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Hepatic Gene Expression Profiles Differentiate Presymptomatic Patients With Mild Versus Severe Nonalcoholic Fatty Liver Disease
Open accessAbstract
Clinicians rely upon the severity of liver fibrosis to segregate patients with well-compensated nonalcoholic fatty liver disease (NAFLD) into subpopulations at high- versus low-risk for eventual liver-related morbidity and mortality. We compared hepatic gene expression profiles in high- and low-risk NAFLD patients to identify processes that distinguish the two groups and hence might be novel biomarkers or treatment targets. Microarray analysis was used to characterize gene expression in percutaneous liver biopsies from low-risk, “mild” NAFLD patients (fibrosis stage 0–1; n = 40) and high-risk, “severe” NAFLD patients (fibrosis stage 3–4; n = 32). Findings were validated in a second, independent cohort and confirmed by real-time polymerase chain reaction and immunohistochemistry (IHC). As a group, patients at risk for bad NAFLD outcomes had significantly worse liver injury and more advanced fibrosis (severe NAFLD) than clinically indistinguishable NAFLD patients with a good prognosis (mild NAFLD). A 64-gene profile reproducibly differentiated severe NAFLD from mild NAFLD, and a 20-gene subset within this profile correlated with NAFLD severity, independent of other factors known to influence NAFLD progression. Multiple genes involved with tissue repair/regeneration and certain metabolism-related genes were induced in severe NAFLD. Ingenuity Pathway Analysis and IHC confirmed deregulation of metabolic and regenerative pathways in severe NAFLD and revealed overlap among the gene expression patterns of severe NAFLD, cardiovascular disease, and cancer. Conclusion : By demonstrating specific metabolic and repair pathways that are differentially activated in livers with severe NAFLD, gene profiling identified novel targets that can be exploited to improve diagnosis and treatment of patients who are at greatest risk for NAFLD-related morbidity and mortality. (Hepatology 2014;59:471–482)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
D'Amico, G., Garcia-Tsao, G., & Pagliaro, L. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.013 · Cited by 2,687
Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Angulo, P., Keach, J. C., Batts, K. P., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510300604 · Cited by 1,610
Yamaguchi, K., Yang, L., McCall, S., Huang, J., Yu, X. X., Pandey, S. K., Bhanot, S., Monia, B. P., Li, Y.-X., & Diehl, A. M. (2007) · Hepatology · doi:10.1002/hep.21655 · Cited by 1,015
Self-citationA comparison of background correction methods for two-colour microarrays
Ritchie, M. E., Silver, J., Oshlack, A., Holmes, M., Diyagama, D., Holloway, A., & Smyth, G. K. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm412 · Cited by 907
Cited by
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Schwabe, R. F., Tabas, I., & Pajvani, U. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.311 · Cited by 671
Tsuchida, T., Lee, Y. A., Fujiwara, N., Ybanez, M., Allen, B., Martins, S., Fiel, M. I., Goossens, N., Chou, H.-I., Hoshida, Y., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.011 · Cited by 583
Pathogenesis of Nonalcoholic Steatohepatitis
Machado, M. V., & Diehl, A. M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.066 · Cited by 539
Self-citationGovaere, O., Cockell, S., Tiniakos, D., Queen, R., Younes, R., Vacca, M., Alexander, L., Ravaioli, F., Palmer, J., Petta, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba4448 · Cited by 479
Sphingolipids and phospholipids in insulin resistance and related metabolic disorders
Meikle, P. J., & Summers, S. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.169 · Cited by 423
Relationship Between Methylome and Transcriptome in Patients With Nonalcoholic Fatty Liver Disease
Murphy, S. K., Yang, H., Moylan, C. A., Pang, H., Dellinger, A., Abdelmalek, M. F., Garrett, M. E., Ashley–Koch, A., Suzuki, A., Tillmann, H. L., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.047 · Cited by 391
Self-citationPathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
Haas, J. T., Francque, S., & Staels, B. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105331 · Cited by 394
The role and regulation of the peroxisome proliferator activated receptor alpha in human liver
Kersten, S., & Stienstra, R. (2017) · Biochimie · doi:10.1016/j.biochi.2016.12.019 · Cited by 394
Kumar, S., Duan, Q., Wu, R., Harris, E. N., & Su, Q. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113869 · Cited by 351
Du, K., Hyun, J., Premont, R. T., Choi, S. S., Michelotti, G. A., Swiderska-Syn, M., Dalton, G. D., Thelen, E., Rizi, B. S., Jung, Y., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.12.022 · Cited by 339
Self-citationdu Plessis, J., van Pelt, J., Korf, H., Mathieu, C., van der Schueren, B., Lannoo, M., Oyen, T., Topal, B., Fetter, G., Nayler, S., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.044 · Cited by 325
Arendt, B. M., Comelli, E. M., Ma, D. W. L., Lou, W., Teterina, A., Kim, T., Fung, S. K., Wong, D. K. H., McGilvray, I., Fischer, S. E., et al. (2015) · Hepatology · doi:10.1002/hep.27695 · Cited by 313
Suppli, M. P., Rigbolt, K. T. G., Veidal, S. S., Heebøll, S., Eriksen, P. L., Demant, M., Bagger, J. I., Nielsen, J. C., Oró, D., Thrane, S. W., et al. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00358.2018 · Cited by 282
Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies
Wu, X., Xu, M., Geng, M., Chen, S., Little, P. J., Xu, S., & Weng, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01439-y · Cited by 272
Metabolomic identification of subtypes of nonalcoholic steatohepatitis
Alonso, C., Fernández-Ramos, D., Varela-Rey, M., Martínez-Arranz, I., Navasa, N., Van Liempd, S. M., Lavín Trueba, J. L., Mayo, R., Ilisso, C. P., de Juan, V. G., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.015 · Cited by 263
Teufel, A., Itzel, T., Erhart, W., Brosch, M., Wang, X. Y., Kim, Y. O., von Schönfels, W., Herrmann, A., Brückner, S., Stickel, F., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.05.051 · Cited by 229
Haas, J. T., Vonghia, L., Mogilenko, D. A., Verrijken, A., Molendi-Coste, O., Fleury, S., Deprince, A., Nikitin, A., Woitrain, E., Ducrocq-Geoffroy, L., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0076-1 · Cited by 155
High Prevalence of Nonalcoholic Fatty Liver Disease in Adolescents Undergoing Bariatric Surgery
Xanthakos, S. A., Jenkins, T. M., Kleiner, D. E., Boyce, T. W., Mourya, R., Karns, R., Brandt, M. L., Harmon, C. M., Helmrath, M. A., Michalsky, M. P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.039 · Cited by 151
Acquisition of epithelial plasticity in human chronic liver disease
Gribben, C., Galanakis, V., Calderwood, A., Williams, E. C., Chazarra-Gil, R., Larraz, M., Frau, C., Puengel, T., Guillot, A., Rouhani, F. J., et al. (2024) · Nature · doi:10.1038/s41586-024-07465-2 · Cited by 142
TGFβ2 and TGFβ3 isoforms drive fibrotic disease pathogenesis
Sun, T., Huang, Z., Liang, W.-C., Yin, J., Lin, W. Y., Wu, J., Vernes, J.-M., Lutman, J., Caplazi, P., Jeet, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0407 · Cited by 134
Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis
Yu, J., Zhu, C., Wang, X., Kim, K., Bartolome, A., Dongiovanni, P., Yates, K. P., Valenti, L., Carrer, M., Sadowski, T., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe1692 · Cited by 132
Loft, A., Alfaro, A. J., Schmidt, S. F., Pedersen, F. B., Terkelsen, M. K., Puglia, M., Chow, K. K., Feuchtinger, A., Troullinaki, M., Maida, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.06.005 · Cited by 129
Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice
Alsamman, S., Christenson, S. A., Yu, A., Ayad, N. M. E., Mooring, M. S., Segal, J. M., Hu, J. K.-H., Schaub, J. R., Ho, S. S., Rao, V., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8798 · Cited by 122
Lefebvre, P., Lalloyer, F., Baugé, E., Pawlak, M., Gheeraert, C., Dehondt, H., Vanhoutte, J., Woitrain, E., Hennuyer, N., Mazuy, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92264 · Cited by 117
“Comparing the liver transcriptome of NAFLD patients with no or little fibrosis to the one of fibrotic patients revealed genes involved in cellular proliferation and ECM organization (27, 28).”
BackgroundMethodHepatic stellate cells control liver zonation, size and functions via R-spondin 3
Sugimoto, A., Saito, Y., Wang, G., Sun, Q., Yin, C., Lee, K. H., Geng, Y., Rajbhandari, P., Hernandez, C., Steffani, M., et al. (2025) · Nature · doi:10.1038/s41586-025-08677-w · Cited by 133
Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion
Eriksen, P. L., Vilstrup, H., Rigbolt, K., Suppli, M. P., Sørensen, M., Heebøll, S., Veidal, S. S., Knop, F. K., & Thomsen, K. L. (2019) · Liver International · doi:10.1111/liv.14205 · Cited by 81
Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease
Wiering, L., Subramanian, P., & Hammerich, L. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.02.010 · Cited by 80
Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity
Guy, C. D., Suzuki, A., Abdelmalek, M. F., Burchette, J. L., Diehl, A. M., & CRN, F. T. N. (2015) · Hepatology · doi:10.1002/hep.27235 · Cited by 72
Self-citationHepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH)
Vandel, J., Dubois‐Chevalier, J., Gheeraert, C., Derudas, B., Raverdy, V., Thuillier, D., Gaal, L., Francque, S., Pattou, F., Staels, B., et al. (2021) · Hepatology · doi:10.1002/hep.31312 · Cited by 61
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
Martínez‐Arranz, I., Bruzzone, C., Noureddin, M., Gil‐Redondo, R., Mincholé, I., Bizkarguenaga, M., Arretxe, E., Iruarrizaga‐Lejarreta, M., Fernández‐Ramos, D., Lopitz‐Otsoa, F., et al. (2022) · Hepatology · doi:10.1002/hep.32427 · Cited by 65
van Koppen, A., Verschuren, L., van den Hoek, A. M., Verheij, J., Morrison, M. C., Li, K., Nagabukuro, H., Costessi, A., Caspers, M. P. M., van den Broek, T. J., et al. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.10.001 · Cited by 58
Kostrzewski, T., Snow, S., Battle, A. L., Peel, S., Ahmad, Z., Basak, J., Surakala, M., Bornot, A., Lindgren, J., Ryaboshapkina, M., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02616-x · Cited by 52
Roehlen, N., Saviano, A., El Saghire, H., Crouchet, E., Nehme, Z., Del Zompo, F., Jühling, F., Oudot, M. A., Durand, S. C., Duong, F. H. T., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj4221 · Cited by 54
Sen, P., Govaere, O., Sinioja, T., McGlinchey, A., Geng, D., Ratziu, V., Bugianesi, E., Schattenberg, J. M., Vidal-Puig, A., Allison, M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104949 · Cited by 28
Liu, H., Yin, G., Franco Leonardi, B., Lan, T., Ait Ahmed, Y., Berger, H., Kohlhepp, M. S., Amiridze, N., Martagón Calderón, N., Frau, C., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334425 · Cited by 23
Czepukojc, B., Abuhaliema, A., Barghash, A., Tierling, S., Naß, N., Simon, Y., Körbel, C., Cadenas, C., van Hul, N., Sachinidis, A., et al. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00179 · Cited by 20
One-Carbon Metabolism in Liver Health and Disease
Mato, J. M., Martínez-Chantar, M. L., Noureddin, M., & Lu, S. C. (2017) · Liver Pathophysiology · doi:10.1016/b978-0-12-804274-8.00054-0 · Cited by 12
Metadata
- Authors
- Moylan, C. A., Pang, H., Dellinger, A., Suzuki, A., Garrett, M. E., Guy, C. D., Murphy, S. K., Ashley-Koch, A. E., Choi, S. S., Michelotti, G. A., Hampton, D. D., Chen, Y., Tillmann, H. L., Hauser, M. A., Abdelmalek, M. F., & Diehl, A. M.
- Venue
- Hepatology
- Published
- 2014-02
- Volume
- 59
- Issue
- 2
- Pages
- 471-482
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2137516998
- Cited by
- 316
- References
- 37
- FWCI
- 12.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.